Solid tumors are cancers occurring in organs and tissues throughout the body except for the blood and the brain. St. Jude is setting the standard in combating these tumors through excellent inpatient care and the rational development of novel therapies.
To schedule an interview, email media@stjude.org.
Solid Tumor Experts
-
Michael Dyer, PhD
Dyer
Michael Dyer, PhD, St. Jude Department of Developmental Neurobiology chair and Solid Tumor Program co-leader, studies how issues in developing neural progenitor cells can lead to disease. Dyer leads the Childhood Solid Tumor Network, the world's largest and most comprehensive collection of scientific resources for pediatric solid tumors and related biology.
-
Sara M. Federico, MD
Federico
Sarah Federico, MD, St. Jude Department of Oncology, Solid Tumor Division director, and Solid Tumor Program co-leader, develops and tests novel therapeutic interventions for the treatment of pediatric solid tumors. Federico has successfully spearheaded multiple clinical trials for novel therapeutics aimed at improving the survival of children with solid tumors.
-
Mark E. Hatley, MD, PhD
Hatley
Mark Hatley, MD, PhD, St. Jude Department of Oncology, Division of Molecular Oncology director, researches how developmental features of cells contribute to and define pediatric cancer. His research interests include cellular and molecular origins of embryonal rhabdomyosarcoma, and the development of novel therapies for pediatric sarcomas.
-
Alberto Pappo, MD
Pappo
Alberto Pappo, MD, St. Jude Department of Oncology, is an expert in rare solid tumors. Pappo also leads a pediatric melanoma referral clinic where experts evaluate patients from all over the country to provide invaluable help to referring physicians treating this rare pediatric disease.
-
Julie Park, MD
Park
Julie Park, MD, St. Jude Department of Oncology chair, has a strong track record translating laboratory research findings into early-phase clinical trials for recurrent childhood malignancies. In particular, she collaborated with laboratory investigators in designing the first in-human autologous chimeric antigen receptor (CAR) T-cell trials for pediatric leukemia, solid tumors and brain tumors. Park has also developed novel combinatorial therapies for particularly difficult-to-treat neuroblastomas.
-
Charles W. M. Roberts, MD, PhD
Roberts
Executive Vice President Charles Roberts, MD, PhD, St. Jude Comprehensive Cancer Center director, leads research in the field of cancer epigenetics. Roberts’ work has led to new investigational cancer therapies for both children and adults, studying how chromatin remodeling complexes, which normally allow access to DNA so genes can be transcribed, contribute to cancer.
